PHAT News and Press, Phathom Pharmaceuticals Inc. From 11/01/23

FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 years VOQUEZNA ® met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3 PHALCON-EE trial evaluating VOQUEZNA in comparison to a standard-of-care proton pump in...

2023-10-30 12:32:31 ET More on Phathom Pharma Following Up On Phathom Pharmaceuticals Phathom files for FDA approval of vonoprazan for Non-Erosive GERD Phathom submits additional data to FDA for esophagitis candidate Seeking Alpha’s Quant Rating on Pha...

Planning for a December 2023 U.S. launch for H. pylori , together with the U.S. launch of vonoprazan for Erosive GERD, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on develop...

2023-10-05 12:43:14 ET Summary Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug candidate. The company ended the second quarter w...

2023-09-26 12:25:14 ET More on Phathom Pharmaceuticals Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals Historical earnings data for Phathom Pharmaceuticals Financial information for Phathom Pharmaceuticals Phathom Pharma: Time To Take Profits (...

Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile consistent with prior vonoprazan studies New drug application (NDA) seeks U.S. Food and Drug Ad...

2023-08-21 09:48:10 ET More on Phathom Pharmaceuticals Phathom Pharma: Time To Take Profits (Rating Downgrade) Phathom resubmits vonoprazan application for esophagitis to FDA, announces stock offering Phathom gains as Evercore ISI upgrades on potential vonoprazan app...

Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration (FDA) and continue to support the requested product shelf life Submission of six-month stability data satisfies Phathom's stability data submission requirements for...

2023-08-10 12:23:37 ET Phathom Pharmaceuticals press release ( NASDAQ: PHAT ): Q2 GAAP EPS of -$0.84 beats by $0.14 . As of June 30, 2023, cash and cash equivalents were $248.8 million. For further details see: Phathom Pharmaceuticals GAAP EPS of -$0.84 beats...

Prior Approval Supplement (PAS) for VOQUEZNA ® TRIPLE PAK ® and VOQUEZNA ® DUAL PAK ® assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 30, 2023 by the U.S. Food and Drug Administration (FDA) U.S. commercial launch for H. pylori ...